A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A large real-world cohort study presented at 67th ASH Annual Meeting and Exposition examined whether adding low-dose aspirin to warfarin improves outcomes in patients with antiphospholipid syndrome and...
A large real-world cohort study presented at 67th ASH Annual Meeting and Exposition examined whether adding low-dose aspirin to warfarin improves outcomes in patients with antiphospholipid syndrome and...
A large real-world cohort study presented at 67th ASH Annual Meeting and Exposition examined whether adding low-dose aspirin to warfarin improves outcomes in patients with antiphospholipid syndrome and...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
